@article{oai:u-ryukyu.repo.nii.ac.jp:02016874,
 author = {野口, 洋文 and Noguchi, Hirofumi},
 issue = {1･2},
 journal = {琉球医学会誌 = Ryukyu Medical Journal},
 note = {Type 1 diabetes mellitus is an autoimmune disease characterized by the destruction of the islets of Langerhans cells, which produce insulin. Pancreatic islet transplantation is a promising option for the treatment of patients with type 1 diabetes who experience hypoglycemic unawareness despite receiving maximal care. Following the successful demonstration of the Edmonton protocol, more than 1,000 patients with type 1 diabetes have been treated at more than 50 institutions using islet transplantation. Clinical islet isolation is currently performed in a Good Manufacturing Practice (cGMP) islet processing facility, called a Cell Processing Center (CPC). The protocol for islet isolation has shown significant advancements on several fronts, including pancreatic ductal protection, improvements in pancreas preservation systems, a new islet purification method and culture/preservation of isolated islets. In this article, we review the current state of research regarding pancreatic islet transplantation., 論文},
 pages = {9--12},
 title = {[総説]臨床膵島移植と細胞処理センター},
 volume = {34}
}